Keyword: Proteus Biomedical
As patients continue taking a more active role in healthcare, pharma's interest in digital therapeutics, already on a roll, will only accelerate.
Cancer drugmakers cut prices by 56.7% for China; Celltrion's Rituxan biosim wins FDA panel support; Otsuka renews digital pill deal with Proteus.
The new digital Abilify is a breakthrough for Proteus Digital Health and its patient-tracking products, but not so much for Abilify's maker, Otsuka.
Back in September, Otsuka and partner Proteus Digital Health submitted an application to the FDA for their new drug adherence device. The agency reviewed the submission and, underwhelmed by what it found, said that it needs more information before it gives its final stamp of approval.